| | Stress is a constant companion in the oncologist's office. It appears at the time of diagnosis, increases with each stage of treatment, and often does not resolve even after therapy formally ends. It accompanies therapeutic decisions, waiting for test results, fear of recurrence, and changes in daily functioning. Studies show that chronic stress can trigger biological processes that promote disease progression and weaken the body's defenses. | |
|
| | Chronic inflammation can raise a person's risk of cancer, and a new study reveals key details about how that might happen in the gut and points to better ways to identify and reduce risk. | |
|
| | A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery. | |
|
| | A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers. | |
|
| | A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high accuracy. | |
|
| |  Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years. | |
|
| |  In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients. | |
|
| |  Australian researchers have uncovered a critical mechanism driving the growth and spread of glioblastoma – one of the most aggressive and lethal forms of brain cancer – potentially paving the way for more effective treatments. | |
|
| |  A copper-based agent complex kills cancer cells in a novel way. It receives its activation signal through light. It could help where existing chemotherapy treatments reach their limits. | |
|
| |  Neither radiologists nor multimodal large language models (LLMs) are able to easily distinguish artificial intelligence (AI)-generated "deepfake" X-ray images from authentic ones, according to a study published today in Radiology, a journal of the Radiological Society of North America (RSNA). | |
|
| |  Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the armpit (the axilla), by having radiotherapy instead. | |
|
| | An international team led by researchers at Baylor College of Medicine, Texas Children's Hospital, McGill University and University of Pittsburgh School of Medicine has discovered what drives the growth of a lethal pediatric brain tumor called Posterior Fossa Type A (PFA) ependymoma. | |
|
| |  Researchers found that both radiologists and multimodal AI models had only moderate success distinguishing synthetic radiographs from real clinical images, even when told fakes were present. The study warns that increasingly realistic AI-generated X-rays could be misused in medicine, research, insurance, and litigation, strengthening the case for watermarking, clinician training, and dedicated detection tools. | |
|
| |  The thymus is a small organ located in the upper chest that plays a central role in the immune system: it produces T cells - specialized immune cells that recognize and fight pathogens. | |
|
| |  Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer can predict whether they are likely to relapse, especially when samples are taken after the patients have received treatments prior to surgery. | |
|
| |  Damon Runyon scientists and industry partners gathered on Tuesday, March 24, for the 2026 Accelerating Cancer Cures Research Symposium, hosted by Amgen in Cambridge, Massachusetts. | |
